Neuburgh Advisers LLC Takes Position in Takeda Pharmaceutical Co Ltd (NYSE:TAK)

Neuburgh Advisers LLC purchased a new stake in Takeda Pharmaceutical Co Ltd (NYSE:TAK) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 8,096 shares of the company’s stock, valued at approximately $143,000.

Several other hedge funds also recently bought and sold shares of the company. Coastal Investment Advisors Inc. grew its position in shares of Takeda Pharmaceutical by 59.8% in the second quarter. Coastal Investment Advisors Inc. now owns 1,718 shares of the company’s stock valued at $32,000 after purchasing an additional 643 shares in the last quarter. Shelton Capital Management purchased a new position in Takeda Pharmaceutical in the first quarter worth approximately $46,000. Advisory Services Network LLC grew its position in Takeda Pharmaceutical by 101.6% in the second quarter. Advisory Services Network LLC now owns 2,076 shares of the company’s stock worth $37,000 after acquiring an additional 1,046 shares during the period. Global Retirement Partners LLC grew its position in Takeda Pharmaceutical by 63.3% in the first quarter. Global Retirement Partners LLC now owns 3,421 shares of the company’s stock worth $70,000 after acquiring an additional 1,326 shares during the period. Finally, Gabelli Funds LLC grew its position in Takeda Pharmaceutical by 0.4% in the second quarter. Gabelli Funds LLC now owns 348,712 shares of the company’s stock worth $6,172,000 after acquiring an additional 1,400 shares during the period. Institutional investors and hedge funds own 9.27% of the company’s stock.

NYSE:TAK traded up $0.25 during trading hours on Friday, reaching $17.43. 30,213 shares of the stock were exchanged, compared to its average volume of 1,006,431. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.46 and a quick ratio of 1.01. The stock has a 50-day simple moving average of $17.10. Takeda Pharmaceutical Co Ltd has a twelve month low of $15.50 and a twelve month high of $21.95. The stock has a market cap of $26.67 billion, a P/E ratio of 34.11 and a beta of 0.70.

Several research analysts recently weighed in on TAK shares. Zacks Investment Research lowered Takeda Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Wednesday, August 7th. Daiwa Capital Markets lowered Takeda Pharmaceutical from an “outperform” rating to a “neutral” rating in a research report on Thursday, August 15th.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.

See Also: How can investors benefit from after-hours trading?

Institutional Ownership by Quarter for Takeda Pharmaceutical (NYSE:TAK)

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit